1. AB0294 Long-term comprehensive disease control with certolizumab pegol regardless of concomitant dmards: results from the japanese cohort. (23rd January 2014) Authors: Tanaka, Y.; Yamamoto, K.; Takeuchi, T.; Yamanaka, H.; Ishiguro, N.; Eguchi, K.; Watanabe, A.; Origasa, H.; Okamoto, T.; Shoji, T.; Miyasaka, N.; Koike, T. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A876 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0468 Improved physical function, pain, and health related quality of life with certolizumab pegol in japanese rheumatoid arthritis patients with an inadequate response to methotrexate: Results from the jrapid study. (23rd January 2014) Authors: Yamanaka, H.; Yamamoto, K.; Takeuchi, T.; Ishiguro, N.; Tanaka, Y.; Eguchi, K.; Watanabe, A.; Origasa, H.; Shoji, T.; Sakamaki, Y.; Miyasaka, N.; Koike, T. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 664 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0469 Improved physical function, pain, and health related quality of life with certolizumab pegol in japanese rheumatoid arthritis patients without methotrexate co-administration: Results from the hikari study. (23rd January 2014) Authors: Yamanaka, H.; Yamamoto, K.; Takeuchi, T.; Ishiguro, N.; Tanaka, Y.; Eguchi, K.; Watanabe, A.; Origasa, H.; Iwai, K.; Sakamaki, Y.; Miyasaka, N.; Koike, T. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 664 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FRI0201 Immunogenicity of certolizumab pegol without concomitant methotrexate and clinical response in rheumatoid arthritis patients: post-hoc analysis of the hikari study. (23rd January 2014) Authors: Takeuchi, T.; Yamamoto, K.; Yamanaka, H.; Ishiguro, N.; Tanaka, Y.; Eguchi, K.; Watanabe, A.; Origasa, H.; Wada, Y.; Shoji, T.; Miyasaka, N.; Koike, T. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A440 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. FRI0278 The First Early Rheumatoid Arthritis, Certolizumab Pegol, Multicenter, Double-Blind, Randomized, Parallel-Group Study: C-Opera, in Patients Fulfilling the 2010 Acr/Eular Classification Criteria, Demonstrates Inhibition of Joint Damage Progression. (10th June 2014) Authors: Atsumi, T.; Yamamoto, K.; Takeuchi, T.; Yamanaka, H.; Ishiguro, N.; Tanaka, Y.; Eguchi, K.; Watanabe, A.; Origasa, H.; Shoji, T.; Okada, T.; van der Heijde, D.; Miyasaka, N.; Koike, T. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 484 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. SAT0173 Baseline Parameters Identified in Early, Methotrexate-Naïve Rheumatoid Arthritis Patients with Better Outcomes with Certolizumab Pegol+Methotrexate Compared to Placebo+Methotrexate: Post-Hoc Analyses of C-OPERA, A Randomized, Controlled, Phase 3 Study. (9th June 2015) Authors: Atsumi, T.; Yamamoto, K.; Takeuchi, T.; Yamanaka, H.; Ishiguro, N.; Tanaka, Y.; Eguchi, K.; Watanabe, A.; Origasa, H.; Shoji, T.; Togo, O.; Okada, T.; van der Heijde, D.; Miyasaka, N.; Koike, T. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 716 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. SAT0194 Long Term Safety for Tocilizumab in Real-World Setting; 3 Year Follow-Up Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan. (9th June 2015) Authors: Yamamoto, K.; Goto, H.; Hirao, K.; Nakajima, A.; Origasa, H.; Nakasone, A.; Takagi, N.; Totsuka, K. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 725 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. THU0157 Clinical Outcomes at Week 104 and Analysis of Associated Baseline Factors after An Initial 1 Year of Certolizumab Pegol and MTX Treatment in MTX-Naïve Patients with Early RA: Results from The Second Year of The C-Opera Study. (15th July 2016) Authors: Atsumi, T.; Yamamoto, K.; Takeuchi, T.; Yamanaka, H.; Ishiguro, N.; Tanaka, Y.; Eguchi, K.; Watanabe, A.; Origasa, H.; Shoji, T.; Togo, O.; Okada, T.; van der Heijde, D.; Miyasaka, N.; Koike, T. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 239 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. THU0190 Better Clinical Responses Seen Early with the Loading Dose of Certolizumab Pegol are Maintained until One Year. (10th June 2014) Authors: Takeuchi, T.; Yamamoto, K.; Yamanaka, H.; Ishiguro, N.; Tanaka, Y.; Eguchi, K.; Watanabe, A.; Origasa, H.; Kobayashi, M.; Shoji, T.; Togo, O.; Miyasaka, N.; Koike, T. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. THU0199 Week 12 Clinical Response to Certolizumab Pegol Predicts Long-Term Outcomes Regardless of Concomitant Medications and Baseline Disease Characteristics in Japanese Patients with Active Rheumatoid Arthritis. (23rd January 2014) Authors: Yamanaka, H.; Yamamoto, K.; Takeuchi, T.; Ishiguro, N.; Tanaka, Y.; Eguchi, K.; Watanabe, A.; Origasa, H.; Shoji, T.; Onodera, S.; Miyasaka, N.; Koike, T. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A231 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗